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Tubulointerstitial fibrosis is an integral part of the structural
changes of the kidney in chronic progressive renal failure.
The accumulation of the extracellular matrix in the
tubulointerstitial space is mediated mainly by myofibroblasts.
These are derived from resident interstitial fibroblasts,
tubular epithelial cells, periadventitial cells, and possibly also
mesenchymal stem cells and endothelial cells. Fibrosis is
usually preceded by tubulointerstitial infiltration of
mononuclear inflammatory cells. Proteinuria is one of several
mechanisms of primary glomerular or vascular disease to
transmit the disease process to the interstitial space.
Increased protein filtration may have direct toxic effects on
tubular epithelial cells, induce chemokine and cytokine
secretion and result in increased expression of adhesion
molecules, all contributing to the influx of mononuclear cells.
Inflammatory cells in return secrete cytokines, which
stimulate resident fibroblasts and tubular epithelial cells to
differentiate into matrix-producing cells. The phenotypic
conversion of primary epithelial cells into mesenchymal cells,
termed epithelial-mesenchymal transition (EMT), has been
studied in great detail in recent years. Several signal
transduction pathways of this process have been clarified
and may eventually result in novel therapeutic approaches.
The severity of proteinuria and the extent of EMT have both
been associated with the decline in renal function in clinical
studies. Limiting proteinuria results in a slower decline of
renal function deterioration, whereas reducing EMT has had
beneficial effects in a number of animal studies, including
those indicating reversal of fibrotic lesions. However, the
association between proteinuria and EMT and vice versa is far
from clear and has not been carefully studied.
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TUBULOINTERSTITIAL FIBROSIS
Virtually every form of chronic progressive renal disease is
accompanied by extracellular matrix deposition within the
tubulointerstitium, tubular atrophy, and tubular dilatation.1
Such a fibrotic process is also a morphological correlate of
progressive organ failure in other organs including the liver,
lung, and heart. Fibrogenesis is almost always preceded by
primary (rarely) or much more commonly by secondary
interstitial inflammation (mainly because of glomerular
disease). Interstitial inflammation is characterized mainly
by the influx of mononuclear cells. In almost all forms of
primary or secondary glomerular disease, interstitial infil-
trates have been described.2 Infiltrating mononuclear cells are
composed of monocytes/macrophages and lymphocytes,
particularly T lymphocytes.3 The degree of interstitial
infiltrate correlates with renal function, in particular the
number of tissue CD4-positive T cells is correlated closely
with renal function3 as is the number of CD3 T cells bearing
the chemokine receptors CCR5 and CxCR3.4,5 These
inflammatory cells secrete profibrotic cytokines such as
transforming growth factor (TGF)-b, connective tissue
growth factor or fibroblast growth factor-2, which stimulate
resident interstitial fibroblasts to become myofibroblasts.
These so-called myofibroblasts (the name is because of the de
novo expression of a-smooth muscle actin in these cells,
whose expression is normally restricted to vascular smooth
muscle cells) are the key effector cells in that process albeit
other forms of fibroblast activation may exist.6 In other
organs, myofibroblasts are formed by an intermediate form
entitled the ‘protomyofibroblast’ characterized by the acqui-
sition of contractile stress fibers,7 although the existence of
this form has not been proven in the kidney. The origin of
matrix producing cells in the kidney is a matter of intense
debate and may vary according to the model used.
Myofibroblasts are probably derived mainly from activation
of resident interstitial fibroblasts, although differentiation
processes of periadventitial cells, mesenchymal stem cells or
tubular epithelial cells (see below) may be involved as well.8
In addition, endothelial cells have recently been proposed as
fibroblast precursors in the heart9 and kidney. Very similar
mechanisms of myofibroblast formation have been described
in the liver10 and lung,11 indicating that these cells may have
different precursors. However, not all matrix synthesizing
cells are myofibroblasts and not all myofibroblasts contribute
to interstitial matrix deposition, suggesting a considerable
amount of heterogeneity of these cells.8
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PROTEINURIA AND PROGRESSION
Persistent high-grade proteinuria is an ominous sign in most
human glomerulopathies with the exception of minimal
change disease. Protein excretion itself may result in
tubulointerstitial inflammation and progression of renal
disease because the extent of proteinuria correlates relatively
well with the progression of glomerulopathies.12 In the
Modification of Diet in Renal Disease study, patients with
higher baseline proteinuria experienced a faster decline in
renal function.13 Similarly, in the Ramipril Efficacy in
Nephropathy study, reduction from baseline in urinary
protein excretion predicted the risk of doubling levels of
serum creatinine.14
How could proteinuria result in tubulointerstitial damage?
Different mechanisms are possible, including direct tubular
toxicity, changes in tubular epithelial metabolism, induced
synthesis of cytokines and chemokines and increased
expression of adhesion molecules.15 Increased glomerular
permeability to proteins is associated with augmented
tubular reabsorption of proteins subsequently degraded
through the lysosomal processing pathway. Excess reabsorp-
tion in the proximal tubule may cause lysosomal rupture,
resulting in direct tubular toxicity. The activity of several
lysosomal enzymes (cathepsin B and L) increased in rats with
PAN nephrosis, particularly in the S2 segment of the
proximal tubule.16 However, the capability of proteins to
induce direct tubular toxicity may vary. Using a tubular
perfusion system, Sanders et al.17 found great variability in
the tubular toxicity of low molecular weight proteins. This
may explain, at least in part, why albuminuria alone does not
appear harmful to humans and why patients with nephrotic
syndrome and exclusive albuminuria rarely have tubulointer-
stitial disease.18 Reduction of proteinuria, by dietary protein
restriction or by the use of converting enzyme inhibitors
lowers the urinary excretion of lysozyme and thus, likely,
tubular damage.19 In adriamycin-induced glomerulosclerosis,
the degree of proteinuria parallels the interstitial infiltrate.20
In addition, direct tubular toxicity is not the only effect of
proteinuria. Kees-Folts et al.21 described in bovine serum
albumin-induced overload proteinuria a novel chemotactic
factor for macrophages that was generated in rat proximal
tubule cells as a result of the metabolism of albumin borne
fatty acids but not when lipid depleted bovine serum albumin
was used. Proximal tubular epithelial cells that were
challenged with plasma proteins secreted chemokines such
as monocyte chemoattractant protein-1 and RANTES, which
in return simulated the influx of mononuclear cells into the
interstitium.22,23 Similarly, fractalkine, a chemokine promoting
mononuclear cell adhesion was inducible by proteinuria.24 The
fractalkine receptor CX3CR1 is expressed in infiltrating
mononuclear cells and interstitial fibroblasts.
Hydrogen peroxide was a very potent and sole stimulator
of CX3CR1 expression of fibroblasts.25 Hydrogen peroxide
may be generated by proteinuria in human proximal tubular
cells.26 In addition to inducing increased chemokine secre-
tion, proteins may induce tubular cytokine secretion directly,
such as TGF-b1,27 the most potent inducer of epithelial–me-
senchymal transition (EMT). Still, little evidence remains
showing a close association between the degree of proteinuria
and EMT (see below).
Increased expression of adhesion molecules induced by
proteinuria may also be involved in mediating interstitial
inflammation. Intercellular adhesion molecule-1 and vascular
adhesion molecule-1 are two characteristic examples. Inter-
cellular adhesion molecule-1 binds to the CD11a–CD18
complex expressed on various leukocytes, whereas vascular
adhesion molecule-1 attaches to very late antigen-4 (or a4b1
integrin). In a study of 119 human renal biopsies, the level of
expression of both adhesion molecules correlated well with
the formation of interstitial infiltrates and the degree of
tubulointerstitial fibrosis.28 Using nephrotoxic serum ne-
phritis as a model of antiglomerular basement membrane
disease, intercellular adhesion molecule-1 deficient mice had
significant less interstitial inflammation and subsequent
matrix deposition compared to controls.29 In addition,
Zhang et al.30 were able to demonstrate that intercellular
adhesion molecule-1 is required for the induction of TGF-b1
synthesis in proximal tubule cells. Finally, the direct
stimulation of T cells by tubular epithelial cells as classic
antigen presenting cells is likely very rare. Although increased
or aberrantly expressed class II major histocompatibility
complex antigens have been recognized in a variety of
glomerular diseases, the expression of required co-stimula-
tory molecules such as B7-1 or B7-2 is only rarely detectable.
Figure 1 illustrates these effects of proteinuria on tubular
epithelial cells.
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Figure 1 | Effects of proteinuria on tubular epithelial cells.
Increased protein absorption by tubular cells may result in direct
tubular toxicity, release of chemokines and cytokines, increased
expression of adhesion and MHC class II molecules along with
co-stimulatory molecules. The net effect is an increased influx
of mononuclear inflammatory cells. The evidence for direct
proteinuria induced EMT is weak.
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EPITHELIAL-TO-MESENCHYMAL TRANSITION
The differentiated state of tubular epithelial cells was long
believed to be absolutely stable after the developmental stage.
Regarding the kidney, tubular epithelial cells (with the
exception of collecting duct epithelia) are characteristically
formed from embryonic mesenchyme by a process entitled
mesenchymal-to-epithelial transition. Conversely, in other
organs, embryonic epithelia may give rise to mesenchymal
cells, a process termed EMT. Greenburg and Hay were the
first to suggest that EMT may occur not only during
embryonic development but also under certain pathological
conditions. They performed in vitro experiments which
indicated that epithelial cells may lose apical–basal polarity
and acquire migratory capacity.31,32 EMT in epithelial cells is
characterized by the disruption of epithelial junctional
complexes and the subsequent loss of cell polarity.33 These
actions are accompanied by morphological changes to a
fibroblastoid morphology, downregulation of epithelial
marker proteins such as E-cadherin, ZO-1 and cytokeratin,
and finally, upregulation of mesenchymal markers including
vimentin, a-smooth muscle actin and fibroblast-specific
protein-1.8
Several in vivo studies have demonstrated the existence of
EMT in kidney disease.34,35 However, the most conclusive
evidence came from a landmark study by Iwano et al.36 using
genetically tagged proximal tubular epithelial cells which
demonstrated that up to 36% of all matrix producing cells
within the tubulointerstitial space may be of tubular
epithelial origin in the model of unilateral ureteral obstruc-
tion. However, the contribution of EMT to the formation of
myofibroblasts may be less in other models.37,38
What is the evidence for EMT in human disease? For
obvious reasons, lineage tracing as has been performed in
animal studies cannot be carried out in human biopsies.
Thus, studies in human biopsies have been limited to early
stages of progressive renal failure including diabetic nephro-
pathy,39 IgA nephropathy,40 lupus nephritis41 and chronic
allograft dysfunction.42 These studies utilized mesenchymal
marker proteins such as vimentin or S100A4, the human
analogue of fibroblast-specific protein-1. The expression of
these mesenchymal marker proteins in tubular epithelial cells
was well correlated with renal function in IgA nephropathy,
lupus nephritis and chronic allograft failure.40,43
EMT is induced in vitro by profibrotic cytokines such as
TGF-b1, epidermal growth factor, and fibroblast growth
factor-2.44,45 TGF-b1 is thought to be the most potent
inducer of EMT.44 Very recently, Jun N-terminal kinase was
shown to mediate, at least in part, TGF-b1 induced EMT in
tracheal epithelial cells.46 It remains to be seen if a similar
function can be observed in renal cells. Besides cytokines,
EMT may be induced by a variety of factors. Zeisberg et al.47
demonstrated that culturing tubular epithelial cells in
interstitial matrix components (e.g. collagen type I) resulted
in EMT whereas culturing in components of the tubular
basement membrane resulted in stabilization of the epithelial
phenotype. It is likely that activation of integrin linked kinase
has an important role in the induction of EMT in that
context; this was shown convincingly in a study by Li et al.48
A third way of inducing EMT is by activation of the plasmin
system. Plasmin, a derivative of plasminogen by proteolytic
cleavage, is a protease critically involved in EMT.49 This
proteolytic cleavage is induced by tissue-type plasminogen
activator (tPA) or urokinase-type plasminogen activator,
both of which are inhibited by plasminogen activator
inhibitor-1. Recently, Zhang et al.50 were able to demonstrate
that plasmin formation from plasminogen induces ERK
phosphorylation and EMT in murine tubular epithelial cells.
This and similar research also showed that mice deficient in
plasminogen or tPA have much lower levels of fibrosis,
EMT35,50 and activity of the matrix metalloproteinase-9.
Matrix metalloproteinase-9 is one of the key enzymes
involved in the degradation of type IV collagen, the main
component of the tubular basement membrane, and its
expression may be controlled by tPA. Thus, lower activity of
matrix metalloproteinase-9 means less degradation of type IV
collagen and, thus, the tubular basement membrane. True to
this concept, the integrity of the tubular basement membrane
was largely preserved in the tPA deficient mice but not in
control mice.50
Very recently, Higgins et al.51 added another piece of EMT
induction to the puzzle. They were able to determine in an
elegant series of studies that hypoxia-inducible factor-1 (HIF-
1) also stimulates EMT in vitro and in vivo. Under hypoxic
conditions, HIF-1a may form complexes with HIF-1b,
inducing connective tissue growth factor and lysyl oxidase-
like protein (LOXL2) expression. This may explain why
hypoxia results in fibrosis and progressive renal failure.52 Loss
of peritubular capillaries that eventually results in hypoxia
has been frequently observed in chronic kidney disease.53,54
In addition, it has been demonstrated that the tight junction
disassembly as an early event in EMT is mediated through a
series of events including activation of partitioning-defective
protein 6, recruitment of Smurf1 to tight junctions and
modulation of RhoA.55 A similar mechanism has recently
been described for EndMT.56
A central mediator in all these EMT activating processes
may be snail, a zinc-finger transcription factor.57 It is
intimately involved in the downregulation of E-cadherin
and ZO-1, two important epithelial–epithelial adhesion
molecules.58,59 Moreover, snail expression is upregulated in
human fibrotic kidneys, and its overexpression results in
kidney fibrosis in transgenic mice.60 Similarly, snail 1 with
snail 2 (slug) were induced early in the course of a model of
leucocyte induced EMT in neonatal mice.61 Finally, it has an
important role in the recently described EMT process in
collecting duct epithelial cells.62 Figure 2 summarizes some of
the possible inducing and signal transduction mechanisms of
EMT.49
Do all tubular epithelial cells have the capability to
undergo EMT? Proximal tubular and distal tubular epithelial
cells have been implicated in EMT. Yamashita et al.63 suggest
that a distinct population of renal progenitor tubular cells
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may undergo EMT. However, studies predominantly suggest
that potentially all tubular epithelial cells possess the capacity
to undergo EMT, even collecting duct epithelial cells, which
are not of mesenchymal origin.62
PROTEINURIA AND EMT
As proteinuria may induce a number of changes in tubular
epithelial cells as outlined above, is there any evidence that
increased protein excretion may induce EMT? Few studies
have addressed the association between proteinuria and EMT.
As outlined above, the process of EMT has been described
mainly in the unilateral ureteral obstruction model where up
to 36% of matrix producing cells are of tubular origin.
Conversely, the contribution of EMT seems much smaller in
other models such as the Habu venom model,38 the model of
chronic folic acid nephropathy (Strutz et al., unpublished
observations) and the model of overload proteinuria,64 the
latter indicating that proteinuria alone is not sufficient to
induce EMT. Conversely, Djamali et al.65 noted a good
correlation between proteinuria and the occurrence of EMT
in a rat model of chronic allograft nephropathy.
Regarding human biopsies, Rastaldi et al.39 studied 133
human biopsies from a variety of renal diseases and found a
close correlation between the appearance of EMT markers
and renal function. But only tubular vimentin expression was
significantly associated with the degree of proteinuria,
whereas all other markers analyzed (including expression of
a-smooth muscle actin and loss of cytokeratin and ZO-1)
were independent of the degree of urinary protein excretion.
Vongwiwatana et al.43 studied the role of EMT in late
allograft dysfunction in 10 biopsies from patients with
tubular atrophy and interstitial fibrosis and 10 controls
(protocol biopsies). A good correlation was found between
EMT markers and renal function (determined by serum
creatinine value), whereas only a decrease of cytokeratin
expression was associated with the degree of proteinuria.
Unfortunately, the sample size in this study was too small to
make a valid conclusion.
REVERSAL OF FIBROSIS
Are fibrotic lesions potentially reversible? Up to a certain
point they may be. Until 10 years ago, fibrotic lesions in
general were thought to be irreversible. Then, in a landmark
clinical study, Fioretto et al.66 demonstrated that glomerular
sclerosis could be reversed in a small group of type I diabetic
patients undergoing pancreas transplantation. More recently,
the reversibility of fibrotic changes was also demonstrated for
the tubulointerstitial space in the same group of patients.67
Reversibility of fibrotic lesions has also been described in
other organs, particularly the liver68 and heart.69
Even more complete reversal of fibrotic lesions was
demonstrated in animal studies. Work by Ma et al.70
demonstrated regression of mild focal segmental glomerulo-
sclerosis in an animal study using treatment with an
angiotensin receptor blocker. Regression has also been
described in other animal models, including the application
of an AT1 receptor antagonist in a model of nitric oxide
deficient hypertensive rats,71 as well as therapy with ACE-
inhibitors in the fifth/sixth nephrectomy model,72 and a
model of reversible unilateral ureteral obstruction.73 An
additional agent that has been shown to induce reversal of
fibrotic lesion is bone morphogenetic protein (BMP)-7.
BMP-7 is a member of the large TGF-b super family and has
important roles in bone and kidney development. In mice, its
expression begins at day 11.5 in the ureteric bud as well as in
the condensing mesenchyme, where it acts as an important
cell survival factor.74 BMP-7 deficient mice display changes of
bone formation, lens development and severe impairment of
renal development, leading to death from renal failure shortly
after birth.75,76 Kidney morphology in these mice displayed
hypoplastic kidneys with dilated collecting ducts separated by
stromal cells and extracellular matrix.76 Unlike other
morphogens, BMP-7 expression persists postnatally, particu-
larly in the distal and medullary collecting tubules, where it
may function as a cellular differentiation factor.77 Its effects
are mediated by binding to a receptor complex composed of
two type I and two type II receptors.78 Downregulated BMP-
7 expression has been described in animal models and in
human chronic kidney disease (Bramlage et al., unpublished
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Figure 2 | Simplified scheme of some inducing mechanisms of
EMT and their signal transduction. (1) TGF-b1 pathway: TGF-b1
binds to the heterocomplex of its type I and type II receptors. The
cytokine activates several pathways including the MAPK and the
PI3 kinase pathways. For EMT, the Smad pathway is central.
Smad2/3 form a complex with Smad4, which translocates to the
nucleus. This pathway is enhanced by RhoA and JNK. Conversely,
Smad7 inhibits Smad dependent EMT (not shown). (2) ILK
pathway: ILK binds to the intracellular domain of b1-integrin,
interacts with the actin cytoskeleton, and activates the AKT/PKB
signaling pathway. (3) Hypoxia pathway: HIF-1a usually becomes
hydroxylated in the presence of sufficient oxygen levels, which
allows subsequent binding of the von Hippel Lindau protein (VHL)
followed by ubiquitination and degradation. Conversely, under
hypoxic conditions, HIF-1a forms a complex with HIF-1b, which
induces EMT by inducing CTGF and lysyl oxidase-like protein
(LOXL2) expression. (4) Plasminogen pathway: uPA and tPA
activate plasminogen to plasmin, which binds to the PAR1
receptor. uPA and tPA are inhibited themselves by the
plasminogen activator inhibitor (PAI-1).
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observations) though not in all studies.79 Regulation of BMP-
7 activity in the kidney, however, is complex as it is not only
determined by the availability of the cytokine itself but also
by the balance of its agonists and antagonists.80 Agonists
include the level of BMP receptor expression, the presence of
Kielin/chordin-like protein,81 gremlin, noggin, or uterine
sensitization-associated gene-1 (USAG-1).82,83 In diabetic
nephropathy upregulation of gremlin expression is possibly
responsible for the loss of BMP-7 activity.82
Hruska et al.84 were the first to administer BMP-7
therapeutically in the chronic unilateral ureteral obstruction
model, demonstrating a 5-day delay in the loss of renal
function and showing superiority to the ACE-inhibitor
enalapril. Similarly, a positive effect on renal fibrogenesis by
BMP-7 was demonstrated in a model of Alport’s disease and
lupus nephritis when therapy was initiated early.85 To
resemble the clinical situation more closely, BMP-7 applica-
tion was delayed in the mouse model of nephrotoxic serum
nephritis. Similarly to the studies described above, BMP-7
resulted in regression of fibrotic changes, specifically, tubular
atrophy. Further, it was shown that BMP-7 counteracted the
effects of TGF-b1 particularly on EMT of tubular epithelial
cells.86 Wang et al.87 obtained similar results in a model of
diabetic nephropathy. Conversely, Ikeda et al.64 applied BMP-
7 to rats undergoing protein overload proteinuria and found
only modest effects on the disease course, possibly resulting
from the fact that tubular atrophy and EMT are not
prominent features in that model. However, BMP-7 has
effects besides inhibition of EMT such as downregulation of
proinflammatory cytokine and chemokine secretion in
mesangial and tubular epithelial cells.88,89
These studies indicate that the former paradigm that
fibrotic lesions are irreversible is likely not true. However, the
majority of studies showing reversibility have been performed
in mild fibrotic lesions, where the underlying architectural
scaffolding was intact and thus restoration was possible.
Conversely, it remains to be determined if robust fibrotic
conditions are truly reversible or if there is a point of no
return, which seems likely.
THERAPEUTIC CONSEQUENCES AND OUTLOOK
What are the therapeutic consequences of the link between
EMT and disease progression? Proteinuria is well-established
as a clinically relevant progression factor and thus should be
minimized as much as possible. Conversely, the link between
proteinuria and EMT is rather weak and not clearly
established. Animal studies suggest that inhibition of EMT
slows the rate of progression, but evidence of this action is
lacking in human disease. Reversal of fibrosis is shown very
convincingly in animal studies and also in human progressive
renal failure if the fibrosis inducing cause can be reversed.
Successful pancreas transplantation for renal disease in type I
diabetic patients represents a characteristic example. Con-
versely, it remains to be seen if fibrosis in human disease can
be reversed pharmacologically even if the cause of induction
cannot be stopped. Finally, we should find out if a point of
no return exists, and, if so, where it is. Clearly, we need to
learn a lot more about EMT in human disease before we can
start treating patients with novel pharmacologic agents.
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